Author/Authors :
Ashraf، نويسنده , , Talat and Hay، نويسنده , , Joel W. and Pitt، نويسنده , , Bertram and Wittels، نويسنده , , Ellison and Crouse، نويسنده , , John and Davidson، نويسنده , , Michael and Furberg، نويسنده , , Curt D. and Radican، نويسنده , , Larry، نويسنده ,
Abstract :
This study analyzed the cost-effectiveness of pravastatin in secondary prevention of coronary artery disease (CAD). The projected risk model in 445 male patients with established CAD and moderately elevated serum low-density lipoprotein cholesterol used results data from 2 placebo-controlled plaque regression trials: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries and Pravastatin, Lipids, and Atherosclerosis in the Carotids. Framingham Heart Study data were used to project the risk of mortality 10 years after myocardial infarction (MI) for incremental male patients in the placebo group who had MI. A Markov process was used to estimate life-years saved, and decision analysis was used to estimate cost. Depending on the patient-risk profile, the midrange estimated cost per life-year saved with pravastatin in secondary prevention of CAD varied from $7,124 to $12,665, which is favorable compared with other widely accepted medical interventions. (Am J Cardiol 1996;78:409–414)
